{"id":362,"date":"2025-12-10T18:31:31","date_gmt":"2025-12-10T18:31:31","guid":{"rendered":"https:\/\/skytrofahcp.com\/aghd\/?page_id=362"},"modified":"2026-02-03T20:58:25","modified_gmt":"2026-02-03T20:58:25","slug":"igf-1-profile","status":"publish","type":"page","link":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/","title":{"rendered":"IGF-1 Profile"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":358,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/igf-1.php","meta":{"_acf_changed":false,"footnotes":"<strong>foresiGHt:<\/strong> A multicenter, randomized, phase 3 placebo-controlled (double-blind) trial of adults with GHD who were GH treatment-na\u00efve or had not received GH treatment during the prior 12 months (N = 259). Primary endpoint was change from baseline in trunk percent fat as measured by DXA at week 38.<sup>1,2<\/sup>"},"class_list":["post-362","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IGF-1 Profile | SKYTROFA\u00ae (lonapegsomatropin-tcgd)<\/title>\n<meta name=\"description\" content=\"Explore the efficacy and safety of once-weekly SKYTROFA\u00ae. See fullPrescribing + Safety Info. Secondary efficacy endpoints - Mean IGF-1SDS normalized at week 38\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGF-1 Profile | SKYTROFA\u00ae (lonapegsomatropin-tcgd)\" \/>\n<meta property=\"og:description\" content=\"Explore the efficacy and safety of once-weekly SKYTROFA\u00ae. See fullPrescribing + Safety Info. Secondary efficacy endpoints - Mean IGF-1SDS normalized at week 38\" \/>\n<meta property=\"og:url\" content=\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/\" \/>\n<meta property=\"og:site_name\" content=\"Skytrofa HCP AGHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T20:58:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/\",\"url\":\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/\",\"name\":\"IGF-1 Profile | SKYTROFA\u00ae (lonapegsomatropin-tcgd)\",\"isPartOf\":{\"@id\":\"https:\/\/skytrofahcp.com\/aghd\/#website\"},\"datePublished\":\"2025-12-10T18:31:31+00:00\",\"dateModified\":\"2026-02-03T20:58:25+00:00\",\"description\":\"Explore the efficacy and safety of once-weekly SKYTROFA\u00ae. See fullPrescribing + Safety Info. Secondary efficacy endpoints - Mean IGF-1SDS normalized at week 38\",\"breadcrumb\":{\"@id\":\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/skytrofahcp.com\/aghd\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Efficacy\",\"item\":\"https:\/\/skytrofahcp.com\/aghd\/efficacy\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IGF-1 Profile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/skytrofahcp.com\/aghd\/#website\",\"url\":\"https:\/\/skytrofahcp.com\/aghd\/\",\"name\":\"Skytrofa HCP AGHD\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/skytrofahcp.com\/aghd\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IGF-1 Profile | SKYTROFA\u00ae (lonapegsomatropin-tcgd)","description":"Explore the efficacy and safety of once-weekly SKYTROFA\u00ae. See fullPrescribing + Safety Info. Secondary efficacy endpoints - Mean IGF-1SDS normalized at week 38","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/","og_locale":"en_US","og_type":"article","og_title":"IGF-1 Profile | SKYTROFA\u00ae (lonapegsomatropin-tcgd)","og_description":"Explore the efficacy and safety of once-weekly SKYTROFA\u00ae. See fullPrescribing + Safety Info. Secondary efficacy endpoints - Mean IGF-1SDS normalized at week 38","og_url":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/","og_site_name":"Skytrofa HCP AGHD","article_modified_time":"2026-02-03T20:58:25+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/","url":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/","name":"IGF-1 Profile | SKYTROFA\u00ae (lonapegsomatropin-tcgd)","isPartOf":{"@id":"https:\/\/skytrofahcp.com\/aghd\/#website"},"datePublished":"2025-12-10T18:31:31+00:00","dateModified":"2026-02-03T20:58:25+00:00","description":"Explore the efficacy and safety of once-weekly SKYTROFA\u00ae. See fullPrescribing + Safety Info. Secondary efficacy endpoints - Mean IGF-1SDS normalized at week 38","breadcrumb":{"@id":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/igf-1-profile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/skytrofahcp.com\/aghd\/"},{"@type":"ListItem","position":2,"name":"Efficacy","item":"https:\/\/skytrofahcp.com\/aghd\/efficacy\/"},{"@type":"ListItem","position":3,"name":"IGF-1 Profile"}]},{"@type":"WebSite","@id":"https:\/\/skytrofahcp.com\/aghd\/#website","url":"https:\/\/skytrofahcp.com\/aghd\/","name":"Skytrofa HCP AGHD","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/skytrofahcp.com\/aghd\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/pages\/362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/comments?post=362"}],"version-history":[{"count":0,"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/pages\/362\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/pages\/358"}],"wp:attachment":[{"href":"https:\/\/skytrofahcp.com\/aghd\/wp-json\/wp\/v2\/media?parent=362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}